NEW YORK – The Michael J. Fox Foundation for Parkinson’s Research will use Verily wearable devices to track disease markers and advance the study of the disease.
More than 800 people will participate in a two-year MJFF-led longitudinal Parkinson’s Progression Markers Initiative. They will be outfitted with a Verily multi-sensor watch that will continuously collect data on movement and physiologic and environmental measures. The goal of the study is to use wearable devices in conjunction with clinic-based data and biospecimen collection to zero in on disease markers with the greatest potential to open promising avenues for further scientific inquiry.
Launched in 2010, the PPMI aims to deepen understanding of Parkinson’s and validate objective measures of the disease. The initiative is currently being carried out at 33 clinical sites around the world with support from 22 industry partners. Participants are followed for at least five and up to 13 years and include volunteers with Parkinson’s disease or at-risk for Parkinson’s, as well as control volunteers.
Verily and PPMI will make raw and curated data available to the worldwide research community to drive independent studies in Parkinson’s therapeutic development.
“Expanding this resource through data science and wearable computing holds the potential to deepen understanding of Parkinson’s disease and gain meaningful insights that can inform care and therapeutic development decisions,” said Todd Sherer, CEO of the Michael J. Fox Foundation, in a statement. “This is why PPMI was built, and will help fulfill its tremendous promise for people with PD.”
In addition to this study, MJFF and Verily are partners in the Accelerating Medicines Partnership Parkinson’s disease program, a public-private collaboration between the National Institutes of Health, MJFF and five life sciences companies and managed by the Foundation for the NIH. AMP PD is applying state-of-the-art cellular profiling technologies to samples collected through PPMI and other large-scale studies to define the molecular fingerprint of Parkinson’s disease. Data and analysis generated through that initiative will be available through the AMP PD Knowledge Portal, created by Verily.
Additionally, Verily and MJFF have collaborated on the promotion of the company’s Liftware, a selection of adaptive products designed as aids to people with hand tremor or limited mobility.